TABLE 3.
Plasma concentration of amyloid β1–42 (Aβ1–42) by time in the patients with Alzheimer’s disease.
| Total samples N = 32 | p-value | APOE4(+)$ N = 9 | APOE4(−)# N = 23 | p-value | CDR = 0.5 | CDR > 0.5 | p-value | |
| Aβ1–42 pg/ml (mean ± SD) | p = 0.042 | |||||||
| Time (h) | ||||||||
| 0 | 45.0 ± 41.3 | 31.2 ± 6.5 | 50.4 ± 47.7 | 0.031 | 40.9 ± 28.5 | 47.2 ± 47.1 | 0.691 | |
| 0.5 | 47.8 ± 27.1 | 37.5 ± 7.6 | 51.9 ± 30.8 | 0.043 | 44.9 ± 16.8 | 49.4 ± 31.4 | 0.663 | |
| 1 | 48.6 ± 28.9 | 39.6 ± 8.2 | 52.1 ± 33.3 | 0.112 | 46.0 ± 13.7 | 49.9 ± 34.6 | 0.721 | |
| 2 | 51.6 ± 26.7 | 42.6 ± 9.5 | 55.1 ± 30.5 | 0.086 | 48.7 ± 12.7 | 53.1 ± 31.9 | 0.671 | |
| 3 | 53.0 ± 22.6 | 45.1 ± 9.1 | 56.1 ± 25.5 | 0.112 | 50.8 ± 11.4 | 54.2 ± 26.8 | 0.699 | |
| 5 | 52.9 ± 18.2 | 46.9 ± 9.5 | 55.3 ± 20.4 | 0.263 | 52.2 ± 11.2 | 53.3 ± 21.3 | 0.867 | |
| 8 | 55.1 ± 19.0 | 48.4 ± 10.3 | 57.8 ± 21.1 | 0.170 | 52.9 ± 9.2 | 56.3 ± 22.7 | 0.632 | |
| 24 | 63.6 ± 59.4 | 60.8 ± 42.4 | 64.7 ± 65.7 | 0.621 | 52.6 ± 9.5 | 69.4 ± 72.9 | 0.455 | |
| Increased* (n/N, %) | (28/32, 87.5%) | 8/9, 88.9% | 20/23, 87.0% | 1.000 | 9/11, 81.8% | 19/21, 90.5% | 0.427 | |
CDR, Clinical Dementia Rating. *Defined as 24 h level – baseline level ≥ 0. $At least having an allele of apolipoprotein E4 gene. #No allele of the apolipoprotein E4 gene.